Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Gregory C. Downs
Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia
Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 14 March 2024 / Approved: 15 March 2024 / Online: 18 March 2024 (01:26:18 CET) Seto, A.; Downs, G.; King, O.; Salehi-Rad, S.; Baptista, A.; Chun, K.; Grenier, S.; Nwachukwu, B.; Minden, M.D.; Smith, A.; Capo-Chichi, J. Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia. Preprints 2024, 2024030904.
Multisite clinical cross-validation and variant interpretation of a next generation sequencing panel for lymphoid cancer prognostication
Discussion Molecular sequencing assays for lymphomas are under-represented in clinical laboratories despite the growing evidence for clinical actionability of discrete genomic targets.
Clinical reporting for personalized cancer genomics requires extensive access to subscription-only literature
Abstract Objective: Medical care for cancer is increasingly directed by genomic laboratory testing for alterations in the tumor genome that are significant for diagnosis, prognosis and therapy. Uniquely in medicine, providers must search the biomedical literature for each patient to determine the clinical significance of these alterations. Access to published scientific literature is frequently subject to high fees, with access limited to institutional subscriptions.
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma | Nature Communications
Abstract This multi-centre, non-randomized, open-label, phase II trial (NCT03016338), assessed niraparib monotherapy (cohort 1, C1), or niraparib and dostarlimab (cohort 2, C2) in patients with recurrent serous or endometrioid endometrial carcinoma. The primary endpoint was clinical benefit rate (CBR), with ≥5/22 overall considered of interest. Secondary outcomes were safety, objective response rate (ORR), duration of response, progression free survival and overall survival.
Constitutional Convention, Ratification, and the Bill of Rights
First Amendment: Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the people peaceably to assemble, and to petition the Government for a redress of grievances.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Gregory C.
Contact Gregory C., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack